Telephone
N/A
Address
107 Rundle Street Kent Town, South Australia (SA) 5067
Description
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.11 - 0.32
Trade Value (12mth)
AU$30,548.00
1 week
-4.76%
1 month
-6.98%
YTD
-30.37%
1 year
5.33%
All time high
0.71
EPS 3 yr Growth
42.20%
EBITDA Margin
-25.60%
Operating Cashflow
-$8m
Free Cash Flow Return
-32.00%
ROIC
-36.40%
Interest Coverage
-85.40
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
229m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
26 August 24 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
26 August 24 |
Full Year Financial Results
×
Full Year Financial Results |
26 August 24 |
Investor Presentation 30 June 2024 Results
×
Investor Presentation 30 June 2024 Results |
26 August 24 |
Appendix 4G
×
Appendix 4G |
23 August 24 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
02 August 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
02 August 24 |
Notification regarding unquoted securities - EYE
×
Notification regarding unquoted securities - EYE |
08 July 24 |
Record Sales Results
×
Record Sales Results |
08 July 24 |
Presentation FY24 Sales
×
Presentation FY24 Sales |
31 May 24 |
USA Medicare Update
×
USA Medicare Update |
10 May 24 |
Notification regarding unquoted securities - EYE
×
Notification regarding unquoted securities - EYE |
10 May 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
19 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
19 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
19 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
19 March 24 |
Change in substantial shareholding from AEF
×
Change in substantial shareholding from AEF |
19 March 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
15 March 24 |
Retail Offer Complete
×
Retail Offer Complete |
15 March 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
05 March 24 |
EYE February sales update
×
EYE February sales update |
23 February 24 |
Cleansing Notice
×
Cleansing Notice |
23 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
22 February 24 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
19 February 24 |
Retail Entitlement Offer Booklet
×
Retail Entitlement Offer Booklet |
19 February 24 |
Despatch of Entitlement offer Completed
×
Despatch of Entitlement offer Completed |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.